methylene blue - Profile
✉ Email this page to a colleague
What are the generic sources for methylene blue and what is the scope of patent protection?
Methylene blue
is the generic ingredient in two branded drugs marketed by Chengdu Shuode, Hikma, Meitheal, Nexus, Steriscience, Xiromed, Zydus Lifesciences, and Provepharm Sas, and is included in eight NDAs. Additional information is available in the individual branded drug profile pages.Summary for methylene blue
| US Patents: | 0 |
| Tradenames: | 2 |
| Applicants: | 8 |
| NDAs: | 8 |
US Patents and Regulatory Information for methylene blue
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chengdu Shuode | METHYLENE BLUE | methylene blue | SOLUTION;INTRAVENOUS | 219550-001 | Dec 23, 2025 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Hikma | METHYLENE BLUE | methylene blue | SOLUTION;INTRAVENOUS | 216959-001 | Dec 17, 2024 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Meitheal | METHYLENE BLUE | methylene blue | SOLUTION;INTRAVENOUS | 217380-001 | Jan 23, 2025 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Nexus | METHYLENE BLUE | methylene blue | SOLUTION;INTRAVENOUS | 217561-001 | Nov 21, 2024 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Steriscience | METHYLENE BLUE | methylene blue | SOLUTION;INTRAVENOUS | 216955-001 | Nov 22, 2024 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
